Tengion Issued Additional Notice of Allowance for U.S. Patent Application Covering Cell-Scaffold Regeneration for its Neo

  Tengion Issued Additional Notice of Allowance for U.S. Patent Application
   Covering Cell-Scaffold Regeneration for its Neo-Urinary Conduit™ Product

PR Newswire

WINSTON-SALEM, N.C., Nov. 8, 2012

WINSTON-SALEM, N.C., Nov. 8, 2012 /PRNewswire/ --Tengion, Inc. (OTCQB: TNGN),
a leader in regenerative medicine, today announced that the United States
Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S.
Patent Application No. 12/612,606, titled "Cell-Scaffold Constructs."The
application includes compositional claims on the construct and cellular
elements of Tengion's most advanced product candidate, the Neo-Urinary
Conduit™, as well as use claims covering this technology in additional
clinical applications.

"This Notice of Allowance demonstrates the value of the proprietary technology
behind our Neo-Urinary Conduit and further solidifies the strength and breadth
of our intellectual property portfolio," said John Miclot, Tengion's President
and Chief Executive Officer. "The issuance of this Notice of Allowance,
together with the Notice we received for the Neo-Kidney Augment™ earlier this
month, is evidence of Tengion's dedication to implementing an effective,
long-term patent strategy."

Once issued, this patent will provide Tengion broad protection through 2030
for the regeneration, reconstruction, repair, augmentation or replacement of
laminarly organized luminal organs or tissue structures using scaffolds and
cells that are not derived from the diseased organs or tissues.

"This patent also represents a broad platform opportunity for multiple
neo-organs and cell-based therapies of tubular and hollow organ regeneration,"
Mr. Miclot continued. "We believe this patented technology has therapeutic
applications in several additional indications and this Notice of Allowance is
another major step towards our goal to develop novel therapies for patients
with limited treatment alternatives."

Information on Tengion's patents and pending applications in the United States
can be found on the Patent Application Information Retrieval, or PAIR, system
maintained by the USPTO at http://portal.uspto.gov/external/portal/pair.

About the Neo-Urinary Conduit™
The Neo-Urinary Conduit™ is a combination of a patient's own cells and
bioabsorbable scaffold that is intended to catalyze regeneration of a
native-like urinary tissue conduit, passively transporting urine from the
ureters through a stoma, or hole in the abdomen, into a standard ostomy bag.
Standard of care for patients requiring a non-continent urinary diversion uses
bowel tissue to construct a conduit for urine to exit from the body. There are
over 20,000 urinary diversions performed annually in the United States and
Europe. These patients are at risk for complications associated with the use
of bowel tissue, as well as for those associated with the surgery to harvest
the bowel tissue. The Neo-Urinary Conduit is the only product candidate
currently in development that aims to avoid the use of bowel tissue. The
Neo-Urinary Conduit is being evaluated in an ongoing Phase 1 clinical trial in
bladder cancer patients requiring a urinary diversion following bladder
removal (cystectomy). The trial is designed to assess the safety and
preliminary efficacy of the Neo-Urinary Conduit in up to 10 patients, as well
as to translate the surgical procedure successfully used in preclinical animal
models into clinical trials with human patients. Six patients have been
implanted with the Neo-Urinary Conduit to date and the Company is focused on
completing implantation of the remaining patients in the trial by the end of

About Tengion
Tengion, a clinical-stage regenerative medicine company, is focused on
developing its Organ Regeneration Platform™ to harness the intrinsic
regenerative pathways of the body to regenerate a range of native-like organs
and tissues with the goal of delaying or eliminating the need for chronic
disease therapies, organ transplantation, and the administration of
anti-rejection medications. An initial clinical trial is ongoing for the
Company's most advanced product candidate, the Neo-Urinary Conduit™, an
autologous implant that is intended to catalyze regeneration of native-like
urinary tissue for bladder cancer patients requiring a urinary diversion
following bladder removal. The Company's lead preclinical candidate is the
Neo-Kidney Augment™, which is designed to prevent or delay dialysis kidney
transplantation by increasing renal function in patients with advanced chronic
kidney disease. Tengion has worldwide rights to its product candidates.

Forward-Looking Statements
Certain statements set forth above may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995,
including, but not limited to: (i) plans to develop and commercialize its
product candidates, including the Neo-Kidney Augment and the Neo-Urinary
Conduit; and (ii) expectations regarding ongoing and planned preclinical
studies and clinical trials. Although Tengion believes that these statements
are based upon reasonable assumptions within the bounds of its knowledge of
its business and operations, there are a number of factors that may cause
actual results to differ from these statements. Tengion's business is subject
to significant risks and uncertainties and there can be no assurance that
actual results will not differ materially from expectations. Factors which
could cause actual results to differ materially from expectations include,
among others: (i) the FDA could place the Neo-Urinary Conduit clinical trial
on clinical hold; (ii) patients enrolled in the Neo-Urinary Conduit clinical
trial may experience adverse events, which could delay the clinical trial or
cause the Company to terminate the development of its Neo-Urinary Conduit;
(iii) the Company may have difficulty enrolling patients in its clinical
trials, including the Phase 1 clinical trial for the Neo-Urinary Conduit; (iv)
data from the Company's ongoing preclinical studies, including the proposed
GLP program for the Neo-Kidney Augment, may not continue to be supportive of
advancing such preclinical product candidates; and (v) the Company may be
unable to progress its product candidates that are undergoing preclinical
testing, including the Neo-Kidney Augment, into clinical trials and the
Company may not be successful in designing such clinical trials in a manner
that supports development of such product candidates. For additional factors
which could cause actual results to differ from expectations, reference is
made to the reports filed by the Company with the Securities and Exchange
Commission under the Securities Exchange Act of 1934, as amended. The forward
looking statements in this release are made only as of the date hereof and the
Company disclaims any intention or responsibility for updating predictions or
expectations in this release.

SOURCE Tengion, Inc.

Website: http://www.tengion.com
Contact: Investor and Media: Brian Davis, +1-267-960-4802,
Press spacebar to pause and continue. Press esc to stop.